Shame. Still hoping value will return |
I'm out - lost far too much money here - another failed investment |
yes I think you are right - geo-politics and anti-chinese sentiment are playing a major role here but what surprises me is that the NASDAQ listing seems to control London and HK prices. I was expecting and hoping that inclusion in certain chinese indexes and the southbound stock connect program would mean a big influx of chinese investors and that would mean theat the HK listing would become dominant, but that hasn't happened. |
The story and the performance havve not changed. Only the political background holds HCM back. I think the relationship with Takeda will go a long way to fix that. |
I may do that, although I did it at 300p and that clearly didn't work - another failed investment strategy |
Time to double down and load up. |
8 years of progress wiped out, now back below NASDAQ IPO levels of 2016 and below share price levels of mid 2015
The valuation is truly shocking and makes no sense at all any more |
Should see a turn today: Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Great to see the Takeda effect and hope more is to come. HCM also sent another news release at the same time: HUTCHMED Highlights Presentations at
the 2023 ASCO Annual Meeting |
shorts, malaise, geo-politics, anti-china rhetoric, Taiwan etc etc..... |
hmmmm not sure steeple but I'm probably |
https://youtu.be/8LMB6K4rTGU |
Biden Executive order to put restrictions on U.S. companies investing in chinese companies and having operations in China in sectors such as advanced semi-conductors, AI, electronics etc. Whilst the drug/biopharma sector is not mentioned specifically this Order seems to be another nail in the coffin for US listed Chinese companies. Given the fact the NASDAQ price seems to dictate the HK and London prices I think Hutchmed needs to think whether a US listing is in the best interest of shareholders.
This has been an absolute disaster for all those institutional shareholders, many of who took shares at $30.
The company needs to ditch NASDAQ and London, get a Star market listing and maintain the HK one.
The geo-politics mean this has become uninvestable. Massive financial, commercial and clinical progress has made no difference to the Company's valuation |
And Nasdaq price down 6.55% so far today. |
sheer malaise, no interest, low volume, and clearly there will be no decent uplift here for years.....too many people have lost far too much money, and that includes all the institutional investors, some of whom paid $30+ per share.....ouch |
God I hope this gets bought soon |
Hopefully we will get bought at some point soon, the stress of continuing to lose money and holding a company whose value is governed by geo-political risk and activity in the Strait of Taiwan is far too stressful |
No sense at all other than China is at loggerheads with the US and its allies.The geopolitical risk is outweighing Hutchmed’s medical advances.Plus,the management of the company are pretty naive when it comes to dealing with market sentiment and nurturing investors.It is disappointing that the Takeda deal hasn’t altered perception. |
Despite the huge pipeline, clear runway to free cashflow in 2025/6 and massive progress (+ a few setbacks) this is valued the same it it was 8 years ago, which makes no sense at all. |
> HUTCHMED (China) Ltd
250.00 GBX −20.00 (7.41%) |
Apparently Morgan Stanley reinstated HCM China "Equal-Weight" today and yet we are down nearly 7.5% on the day so far. HCM are really being a disappointment re: the share price. |
Aye, might well zap up after this news
Next Resistance seems to be 284p then a huge gap to 335p
Expecting an exciting day
cheers |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
